The study will measure the impact of Cognixion's novel combination of BCI, AI and AR technology on the ability of amyotrophic ...

Positron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative ...

Clene (NASDAQ: CLNN) announced new long-term survival data from the HEALEY ALS Platform Trial, showing that treatment with CNM-Au8® 30 mg significant ...

Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

Four immunoassays for neurofilament light chain (NfL) demonstrate consistent performance in patients with amyotrophic lateral ...

Startup Cognixion, which has developed a noninvasive brain-computer interface, has begun a clinical trial for patients with ...

AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...

A new study compares three types of blood biomarkers: neurofilament light chain proteins, glial acidic proteins and phosphorylated tau 181.

Under current regulations, spouses can receive benefits only if the veteran lived with the disability for at least eight years before dying.

Cognixion announced today that it launched a clinical trial evaluating its integrated, wearable augmented reality and BCI ...

Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.

Recent studies have highlighted a link between amyotrophic lateral sclerosis (ALS) and gut microbiota. This prospective study aimed to evaluate the effects of electroacupuncture combined with Chinese ...